Smarter Cancer Care
Genomic Health delivers the promise and value of precision medicine
with the Oncotype IQ portfolio of genomic tests.
What's New

TAILORx: Transforming the Treatment of Breast Cancer

The Trial Assigning Individualized Options for Treatment (TAILORx) primary study group results have been published in the New England Journal of Medicine.

Real People.
Real Results.
When Amy was diagnosed with breast cancer, she was scared. Her Oncotype DX Breast DCIS Score result made her feel in control.
Healthcare Savings
How much do ineffective cancer treatments cost the healthcare system? In the US alone, Oncotype IQ tests have saved more than $3.5 billion.
Practice Tools

The Eighth Edition AJCC Staging Manual will go into effect in 2018, and it will change staging for T1-2 N0 M0 breast cancer patients.

Latest TAILORx Data
After 5 years, 95% of women with a low Oncotype DX Breast Recurrence Score result were recurrence-free with hormone therapy alone.

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™